Multicenter randomized controlled trial of Yiqi Huoxue formula() for the treatment of ruptured lumbar disc herniation.
10.12200/j.issn.1003-0034.20240543
- Author:
Yu ZHU
1
;
Zhi-Qiang WANG
1
;
Shun LIN
1
;
Ying-Ying YAO
1
;
Xue-Qiang SHEN
1
;
Xiao-Chun LI
1
;
Feng YU
1
;
Xiao-Yang XIONG
2
;
Yi SONG
3
;
Meng-Fei CHEN
4
;
Peng-Fei YU
1
;
Hong JIANG
1
;
Jin-Tao LIU
1
Author Information
1. Suzhou Hospital of Traditional Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Suzhou 215009, Jiangsu, China.
2. Kunshan Hospital of Traditional Chinese Medicine, Suzhou 215313, Jiangsu, China.
3. Suzhou Hospital of Integrated Traditional Chinese and Western Medicine, Suzhou 215101, Jiangsu, China.
4. Suzhou Municipal Hospital, Suzhou 215006, Jiangsu, China.
- Publication Type:English Abstract
- Keywords:
Celecoxib;
Mecobalamin;
Resorption;
Ruptured lumbar disc herniation;
Traditional Chinese medicine therapy;
Yiqi Huoxue formula(益气活血方)
- MeSH:
Humans;
Male;
Female;
Intervertebral Disc Displacement/drug therapy*;
Adult;
Drugs, Chinese Herbal/adverse effects*;
Middle Aged;
Lumbar Vertebrae
- From:
China Journal of Orthopaedics and Traumatology
2025;38(11):1112-1118
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To observe the clinical symptoms and MRI outcomes of patients with ruptured lumbar disc herniation(LDH) through a multicenter randomized controlled study, and to evaluate the clinical efficacy and safety of Yiqi Huoxue formula() in the treatment of this disease.
METHODS:A total of 160 outpatients and inpatients with ruptured LDH admitted to 4 medical centers from January 2023 to June 2023 were selected and randomly divided into the Yiqi Huoxue formula group and the control group, with 80 patients in each group. In the Yiqi Huoxue formula group, there were 43 males and 37 females, with an age of (41.03±9.56) years and a disease duration of (10.45±25.37) days, and the patients were treated with Yiqi Huoxue formula. In the control group, there were 34 males and 46 females, with an age of (42.14±8.73) years and a disease duration of (11.31±21.14) days;during the acute phase, patients in this group could take celecoxib capsules orally, and methylcobalamin orally at the same time. The Japanese Orthopaedic Association (JOA) score, Oswestry disability index (ODI), changes in the volume of herniated disc tissue on MRI, herniation rate, and absorption rate were recorded at the time of enrollment and during follow-ups at the 3rd, 6th, and 12th month after treatment.
RESULTS:A total of 156 patients completed the clinical follow-up, and 4 patients withdrew midway. The clinical symptoms of all patients who completed the study were relieved to varying degrees, and reabsorption of herniated disc tissue was observed in all patients in the Yiqi Huoxue formula group after treatment. For the JOA score:in the Yiqi Huoxue formula group, it was (10.73±2.76) points before treatment and (24.65±2.19) points at the 12th month after treatment;in the control group, it was (11.01±1.20) points before treatment and (17.07±3.26) points at the 12th month after treatment. For the ODI score:in the Yiqi Huoxue formula group, it was (26.21±3.55) points before treatment and (5.65±2.19) points at the 12th month after treatment;in the control group, it was (27.92±2.51) points before treatment and (9.09±2.15) points at the 12th month after treatment. At the 12th month after treatment, the JOA and ODI scores of both groups were better than those before treatment, and the scores of the Yiqi Huoxue formula group were better than those of the control group, with statistically significant differences (P<0.05). In terms of the herniated disc volume and herniation rate on MRI, the Yiqi Huoxue formula group was superior to the control group, with statistically significant differences(P<0.05). Reabsorption occurred in 56.96%(45/79) of patients in the Yiqi Huoxue formula group, which was significantly higher than the 37.66%(29/77) in the control group.
CONCLUSION:After treatment with Yiqi Huoxue formula, patients with ruptured LDH show significant improvement in clinical symptoms and a marked reduction in the volume of herniated discs. During the follow-up period, no obvious adverse drug reactions are observed in patients, and no recurrence of symptoms is found at the last follow-up, indicating that the formula has safe and reliable efficacy.
